Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Galectin Therapeutics Inc.NASDAQ: GALT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $1.31M rose 19.9% year over year, ahead of the -85.5% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -50.3% a year.
Context
- Change in working capital increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +19.9% holds above the trailing-twelve-month pace of -85.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 609K USD
- Year-over-year change
- -73.3%
- 4-year CAGR
- -36.5%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 609K | -73.3% |
| FY2024 | 2024-12-31 | 2.28M | -51.2% |
| FY2023 | 2023-12-31 | 4.68M | -5.8% |
| FY2022 | 2022-12-31 | 4.97M | +32.4% |
| FY2021 | 2021-12-31 | 3.75M | — |
Change in Working Capital vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 change in working capital of $826K is the smallest of the 10 companies compared; the peer median is $2.02M.
- Its year-over-year change of -85.5% is the 7th highest of 8, against a peer median of +272.5%.
- Over three fiscal years its annual growth of -50.3% compares with a peer median of +10.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $16.17M | — | — | — |
| LTM Mar 2026 | $9.99M | +435.9% | — | — | |
| LTM Mar 2026 | $6.69M | -276.3% | — | 361.1% | |
| LTM Mar 2026 | $5.12M | +11.7% | — | — | |
| LTM Mar 2026 | $4.69M | +272.5% | -21.8% | 13022.2% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $4.06M | +273.2% | +64.9% | — |
| LTM Dec 2025 | $2.29M | — | — | — | |
| LTM Mar 2026 | $2.02M | +767.0% | +16.0% | — | |
| LTM Mar 2026 | $1.07M | -65.7% | +4.9% | — | |
| LTM Mar 2026 | $826K | -85.5% | -50.3% | — | |
| Peer median (excluding GALT) | $2.02M | +272.5% | +10.4% | 6691.6% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 2.87M | 2.26M | 2.45M | 1.66M |
| Change in Working Capital | 3.75M | 4.97M | 4.68M | 2.28M | 609K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.69M | 4.24M | 2.67M | (2.07M) | (6.04M) |
| Other Working Capital | 65K | 724K | 2.01M | 4.36M | 6.65M |
| Other Non-Cash Items | 351K | (147K) | 1.13M | 512K | 4.64M |
| Operating Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 30M | 10M | 30M | 30M | 21M |
| Common Stock Issued | 6.81M | 0 | 0 | 1.23M | 5.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (171K) | 0 | 0 | (91K) | 0 |
| Other Financing Activities | 171K | 0 | 10.03M | 91K | 0 |
| Financing Cash Flow | 36.81M | 10M | 40.03M | 31.23M | 26.48M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 12.51M | (21.06M) | 7.07M | (10.54M) | 2.6M |
| Free Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.